Generic Name and Formulations:
Vilazodone HCl 10mg, 20mg, 40mg; tabs.
Indications for VIIBRYD:
Major depressive disorder.
Take with food. Initially 10mg once daily for 7 days, then 20mg once daily for 7 days, then increase to 40mg once daily. Concomitant strong CYP3A4 inhibitors: max 20mg once daily. Concomitant strong CYP3A4 inducers for >14 days: consider increasing dose up to 2-fold over 1–2 weeks; max 80mg daily. Readjust to original level when CYP3A4 inhibitors or inducers (in 14 days) are discontinued.
During or within 14 days of MAOIs; do not start an MAOI during or within 14 days of vilazodone. Concomitant linezolid or IV methylene blue.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults; monitor for clinical worsening or unusual changes. Screen for bipolar disorder. Monitor for serotonin syndrome; discontinue if occurs. Increased risk of bleeding. History of mania/hypomania. Seizure disorder. Angle-closure glaucoma. Volume depleted. Avoid abrupt disruption. Reevaluate periodically. Write ℞ for smallest practical amount. Elderly. Pregnancy; effects on neonate exposed in 3rd trimester (see full labeling). Nursing mothers.
See Contraindications. Avoid alcohol. Increased risk of serotonin syndrome with other serotonergic drugs (eg, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, St. John's Wort) or with drugs that impair serotonin metabolism (eg, MAOIs, linezolid, IV methylene blue). Increased risk of bleeding with concomitant aspirin, NSAIDs, warfarin (monitor), other anticoagulants. Potentiated by strong CYP3A4 inhibitors (eg, itraconazole, clarithromycin, voriconazole); see Adult. Antagonized by strong CYP3A4 inducers (eg, carbamazepine, phenytoin, rifampin); see Adult. Monitor digoxin. Caution with other highly protein-bound drugs.
Selective serotonin reuptake inhibitor + 5-HT1A receptor partial agonist.
Diarrhea, nausea, vomiting, insomnia; hyponatremia/SIADH (esp. in elderly).
Tabs—30; Patient Starter Kit (7x10mg tabs + 7x20mg tabs + 16x40mg tabs; 7x10mg tabs + 23x20mg tabs)—30
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Adjunctive Therapies for Bipolar Disorder Show Promise, Need More Evidence
- Predicting Treatment-Emergent Mania to Tailor Pharmacotherapy in Bipolar Disorder
- Abnormalities of Cortical Thickness in Bipolar Disorder With Auditory Hallucinations
- Prevalence of ADHD Relatively Stable Over Time Despite Increase in Diagnoses
- Genetic Variations Associated With Empathy Affect Psychiatric Conditions
- The Way to the Head May Be Through the Gut: Probiotics for Depression
- Suicide-Screening Toolkit Can Help Identify Youths at High Risk for Suicide
- Agoraphobia: An Evolving Understanding of Definitions and Treatment
- Parental Pressure to Diet Linked With Long-term Harm in Adolescents
- Does Access to Medical Cannabis Reduce Risk for Opioid Abuse?
- Examining Rates of Long-term Opioid Use in Youth With Psychiatric Disorders
- Mortality Rates for Substance Use Disorders, Intentional Injuries Vary Widely By Country
- Facial Emotion Recognition Differentiates Behavioral Variant Frontotemporal Dementia From MDD
- The Challenge of Helping Uninsured Patients While Protecting Practice Finances
- Antidepressants Increase Seizure Risk in Youth and Severely Depressed